Medexus Pharmaceuticals Stock Last Dividend Paid
| MEDXF Stock | USD 1.95 0.03 1.52% |
Fundamental analysis of Medexus Pharmaceuticals allows traders to better anticipate movements in Medexus Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Medexus |
Medexus Pharmaceuticals OTC Stock Last Dividend Paid Analysis
Medexus Pharmaceuticals' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Medexus Pharmaceuticals has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
Medexus Fundamentals
| Return On Equity | -0.57 | |||
| Return On Asset | 0.0218 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 80.42 M | |||
| Shares Outstanding | 20.14 M | |||
| Shares Owned By Insiders | 11.00 % | |||
| Shares Owned By Institutions | 0.38 % | |||
| Price To Earning | 11.00 X | |||
| Price To Book | 1.75 X | |||
| Price To Sales | 0.31 X | |||
| Revenue | 76.7 M | |||
| Gross Profit | 43.67 M | |||
| EBITDA | 14.55 M | |||
| Net Income | (2.88 M) | |||
| Cash And Equivalents | 7.29 M | |||
| Cash Per Share | 0.37 X | |||
| Total Debt | 39.82 M | |||
| Debt To Equity | 3.27 % | |||
| Current Ratio | 0.97 X | |||
| Book Value Per Share | 0.77 X | |||
| Cash Flow From Operations | (1.18 M) | |||
| Earnings Per Share | 0.13 X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 100 | |||
| Beta | 1.63 | |||
| Market Capitalization | 23.56 M | |||
| Total Asset | 139.22 M | |||
| Net Asset | 139.22 M |
About Medexus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medexus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medexus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medexus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Medexus OTC Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.